This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Aceragen Gestione
Gestione criteri di controllo 3/4
Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
Informazioni chiave
John Taylor
Amministratore delegato
US$444.1k
Compenso totale
| Percentuale dello stipendio del CEO | 17.5% |
| Mandato del CEO | less than a year |
| Proprietà del CEO | 17.5% |
| Durata media del management | 4.1yrs |
| Durata media del Consiglio di amministrazione | 4.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$444k | US$78k | -US$23m |
Compensazione vs Mercato: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).
Compensazione vs guadagni: Insufficient data to compare John's compensation with company performance.
AMMINISTRATORE DELEGATO
John Taylor (52 yo)
less than a year
Mandato
US$444,062
Compensazione
Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Associate Director of Human Resources | no data | Nessun dato | Nessun dato | |
| Director of Human Resources | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Technical Operations | no data | Nessun dato | Nessun dato | |
| Global Head of Quality | no data | Nessun dato | Nessun dato | |
| Medical Director & Global Clinical Lead for Oncology | no data | Nessun dato | Nessun dato | |
| Advisor | 4.1yrs | US$993.93k | Nessun dato | |
| Adviser | no data | US$986.13k | Nessun dato |
4.1yrs
Durata media
62yo
Età media
Gestione esperta: ACGN's management team is considered experienced (4.1 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Independent Director | 4.3yrs | US$89.43k | 0.26% $ 8.4k | |
| Chair of the Board of Directors | 8.7yrs | US$1.43m | 0.10% $ 3.2k | |
| Independent Director | less than a year | US$11.88k | Nessun dato | |
| Independent Director | 7.6yrs | US$66.24k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$60.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisor Board | no data | Nessun dato | 14.31% $ 458.0k |
4.3yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: ACGN's board of directors are considered experienced (4.3 years average tenure).